Evidence map›Paper›PMID 22552929›Full record

ArticleAAPS PharmSciTech2012

Preformulation study of NSC-726796.

Duoli Guo, James P Cain, Sean O'Connell, Erin R Gardner, Steven Pisle, William D Figg, S Esmail Tabibi, Samuel H Yalkowsky

Abstract read
In one paragraph

Article in AAPS PharmSciTech, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Duoli GuoCollege of Pharmacy, University of Arizona, Tucson, Arizona 85721, USA. duoliguo@gmail.com
James P Cain
Sean O'Connell
Erin R Gardner
Steven Pisle
William D Figg
S Esmail Tabibi
Samuel H Yalkowsky

Funding

Sample Processing and Analytical Methods Development for New Anticancer AgentsZICSC006536 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$18.1M
Using Clinical Pharmacology Principles to Develop New Anticancer TherapiesZICSC006537 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$14.4M
CCR NIH HHS HHSN261200800001CIntramural NIH HHSNCI NIH HHS HHSN261200800001ENCI NIH HHS N01 CM027142NCI NIH HHS N01-CM-27142
6 · The paper itself

Abstract

A stability-indicating high-performance liquid chromatography method to quantify 2-(2,4-difluorophenyl)-4,5,6,7-tetrafluoroisoindoline-1,3-dione (NSC-726796) and its three main degradation products was developed. This method was used to investigate its degradation kinetics and mechanism. The reaction follows first-order kinetics and appears to be base catalyzed with the maximum stability at pH 1. The products were identified as 2-(2,4-difluorophenylcarbamoyl)-3,4,5,6-tetrafluorobenzoic acid (NSC-749820), 2,4-difluoroaniline, and tetrafluorophthalic acid. The parent drug, NSC-726796, was also found to react with methanol and ethanol. NSC-726796 demonstrates antiangiogenic activity, however, when its degradant NSC749820 does not show antiangiogenic activity.

Indexed as

Angiogenesis InhibitorsAniline CompoundsAnimalsCalorimetry, Differential ScanningChemistry, PharmaceuticalChromatography, High Pressure LiquidDrug StabilityEthanolHydrogen-Ion ConcentrationHydrolysisKineticsMethanolNeovascularization, PhysiologicPhthalic AcidsPhthalimidesRats2-(2,4-difluorophenyl)-4,5,6,7-tetrafluoroisoindoline-1,3-dione2,4-difluoroanilineAngiogenesis InhibitorsAniline CompoundsEthanolMethanolPhthalic AcidsPhthalimidesSolvents

Identifiers

PMID22552929
PMCPMC3364376

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.